Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ultrasound study reveals how fasting and tirzepatide pause impact stomach retention

NCT ID NCT07299084

First seen Jan 11, 2026 · Last updated Jun 13, 2026 · Updated 23 times

Summary

This study looks at how long you need to fast and how stopping the diabetes/weight-loss drug tirzepatide changes the amount of food left in your stomach after a meal. Researchers will use ultrasound to check stomach contents in 40 people with type 2 diabetes or obesity. The goal is to better understand stomach emptying, which can affect safety before procedures like surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Lilly Centre for Clinical Pharmacology

    Singapore, 138623, Singapore

Conditions

The condition(s) this trial relates to.

Obesity Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.